Cargando…

C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice

BACKGROUND: We have demonstrated that vaccination with pDNA encoding cysteine proteinase Type II (CPA) and Type I (CPB) with its unusual C-terminal extension (CTE) can partially protect BALB/c mice against cutaneous leishmanial infection. Unfortunately, this protection is insufficient to completely...

Descripción completa

Detalles Bibliográficos
Autores principales: Doroud, Delaram, Zahedifard, Farnaz, Vatanara, Alireza, Taslimi, Yasaman, Vahabpour, Rouholah, Torkashvand, Fatemeh, Vaziri, Behrooz, Rouholamini Najafabadi, Abdolhossein, Rafati, Sima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134432/
https://www.ncbi.nlm.nih.gov/pubmed/21765963
http://dx.doi.org/10.1371/journal.pntd.0001236
_version_ 1782207986915082240
author Doroud, Delaram
Zahedifard, Farnaz
Vatanara, Alireza
Taslimi, Yasaman
Vahabpour, Rouholah
Torkashvand, Fatemeh
Vaziri, Behrooz
Rouholamini Najafabadi, Abdolhossein
Rafati, Sima
author_facet Doroud, Delaram
Zahedifard, Farnaz
Vatanara, Alireza
Taslimi, Yasaman
Vahabpour, Rouholah
Torkashvand, Fatemeh
Vaziri, Behrooz
Rouholamini Najafabadi, Abdolhossein
Rafati, Sima
author_sort Doroud, Delaram
collection PubMed
description BACKGROUND: We have demonstrated that vaccination with pDNA encoding cysteine proteinase Type II (CPA) and Type I (CPB) with its unusual C-terminal extension (CTE) can partially protect BALB/c mice against cutaneous leishmanial infection. Unfortunately, this protection is insufficient to completely control infection without booster injection. Furthermore, in developing vaccines for leishmaniasis, it is necessary to consider a proper adjuvant and/or delivery system to promote an antigen specific immune response. Solid lipid nanoparticles have found their way in drug delivery system development against intracellular infections and cancer, but not Leishmania DNA vaccination. Therefore, undefined effect of cationic solid lipid nanoparticles (cSLN) as an adjuvant in enhancing the immune response toward leishmanial antigens led us to refocus our vaccine development projects. METHODOLOGY/PRINCIPAL FINDINGS: Three pDNAs encoding L. major cysteine proteinase type I and II (with or without CTE) were formulated by cSLN. BALB/c mice were immunized twice by 3-week interval, with cSLN-pcDNA-cpa/b, pcDNA-cpa/b, cSLN-pcDNA-cpa/b(-CTE), pcDNA-cpa/b(-CTE), cSLN, cSLN-pcDNA and PBS. Mice vaccinated with cSLN-pcDNA-cpa/b(-CTE) showed significantly higher levels of parasite inhibition related to protection with specific Th1 immune response development, compared to other groups. Parasite inhibition was determined by different techniques currently available in exploration vacciation efficacy, i.e., flowcytometry on footpad and lymph node, footpad caliper based measurements and imaging as well as lymph node microtitration assay. Among these techniques, lymph node flowcytometry was found to be the most rapid, sensitive and easily reproducible method for discrimination between the efficacy of vaccination strategies. CONCLUSIONS/SIGNIFICANCE: This report demonstrates cSLN's ability to boost immune response magnitude of cpa/cpb(-CTE) cocktail vaccination against leishmaniasis so that the average parasite inhibition percent could be increased significantly. Hence, cSLNs can be considered as suitable adjuvant and/or delivery systems for designing third generation cocktail vaccines.
format Online
Article
Text
id pubmed-3134432
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31344322011-07-15 C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice Doroud, Delaram Zahedifard, Farnaz Vatanara, Alireza Taslimi, Yasaman Vahabpour, Rouholah Torkashvand, Fatemeh Vaziri, Behrooz Rouholamini Najafabadi, Abdolhossein Rafati, Sima PLoS Negl Trop Dis Research Article BACKGROUND: We have demonstrated that vaccination with pDNA encoding cysteine proteinase Type II (CPA) and Type I (CPB) with its unusual C-terminal extension (CTE) can partially protect BALB/c mice against cutaneous leishmanial infection. Unfortunately, this protection is insufficient to completely control infection without booster injection. Furthermore, in developing vaccines for leishmaniasis, it is necessary to consider a proper adjuvant and/or delivery system to promote an antigen specific immune response. Solid lipid nanoparticles have found their way in drug delivery system development against intracellular infections and cancer, but not Leishmania DNA vaccination. Therefore, undefined effect of cationic solid lipid nanoparticles (cSLN) as an adjuvant in enhancing the immune response toward leishmanial antigens led us to refocus our vaccine development projects. METHODOLOGY/PRINCIPAL FINDINGS: Three pDNAs encoding L. major cysteine proteinase type I and II (with or without CTE) were formulated by cSLN. BALB/c mice were immunized twice by 3-week interval, with cSLN-pcDNA-cpa/b, pcDNA-cpa/b, cSLN-pcDNA-cpa/b(-CTE), pcDNA-cpa/b(-CTE), cSLN, cSLN-pcDNA and PBS. Mice vaccinated with cSLN-pcDNA-cpa/b(-CTE) showed significantly higher levels of parasite inhibition related to protection with specific Th1 immune response development, compared to other groups. Parasite inhibition was determined by different techniques currently available in exploration vacciation efficacy, i.e., flowcytometry on footpad and lymph node, footpad caliper based measurements and imaging as well as lymph node microtitration assay. Among these techniques, lymph node flowcytometry was found to be the most rapid, sensitive and easily reproducible method for discrimination between the efficacy of vaccination strategies. CONCLUSIONS/SIGNIFICANCE: This report demonstrates cSLN's ability to boost immune response magnitude of cpa/cpb(-CTE) cocktail vaccination against leishmaniasis so that the average parasite inhibition percent could be increased significantly. Hence, cSLNs can be considered as suitable adjuvant and/or delivery systems for designing third generation cocktail vaccines. Public Library of Science 2011-07-12 /pmc/articles/PMC3134432/ /pubmed/21765963 http://dx.doi.org/10.1371/journal.pntd.0001236 Text en Doroud et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Doroud, Delaram
Zahedifard, Farnaz
Vatanara, Alireza
Taslimi, Yasaman
Vahabpour, Rouholah
Torkashvand, Fatemeh
Vaziri, Behrooz
Rouholamini Najafabadi, Abdolhossein
Rafati, Sima
C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice
title C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice
title_full C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice
title_fullStr C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice
title_full_unstemmed C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice
title_short C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice
title_sort c-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against leishmania major in balb/c mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134432/
https://www.ncbi.nlm.nih.gov/pubmed/21765963
http://dx.doi.org/10.1371/journal.pntd.0001236
work_keys_str_mv AT dorouddelaram cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice
AT zahedifardfarnaz cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice
AT vatanaraalireza cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice
AT taslimiyasaman cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice
AT vahabpourrouholah cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice
AT torkashvandfatemeh cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice
AT vaziribehrooz cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice
AT rouholamininajafabadiabdolhossein cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice
AT rafatisima cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice